Total
0
Shares
MGC Pharma (ASX:MXC) - Co Founder and Managing Director, Roby Zomer - The Market Herald
Co Founder and Managing Director, Roby Zomer
Source: FinFeed
  • MGC Pharmaceuticals (MXC) has commenced its phase two clinical trial on patients diagnosed with COVID-19
  • The study is evaluating the safety and efficacy of ArtemiC — MGC's natural, immune-modulation formula
  • The trial includes a total of 50 patients at the Nazareth Hospital EMMS and Hillel Yaffe Hospital in Israel.
  • The trial is expected to be completed in September and results could be available as early as the following month
  • MGC Pharma will use the study data to prepare for future trials and discuss the commercial supply and sale of ArtemiC
  • Company shares are trading flat at 2.7 cents each

MGC Pharmaceuticals (MXC) has commenced its phase two clinical trial on patients diagnosed with COVID-19.

The phase two double-blind, placebo-controlled clinical trial is aimed at evaluating the safety and efficacy of ArtemiC, MGC's natural, immune-modulation formulation, in patients who have tested COVID-19 positive.

ArtemiC is made up of Artemisinin, a drug from a fern-like plant and is used against malaria, and Curcumin, which is a chemical that aids in anti-inflammatory and antioxidants.

It is then mixed with Vitamin C and Boswellia serrata, which is a herbal extract used to treat inflammatory illnesses.

The trial will include a total of 50 patients at the Nazareth Hospital EMMS and
Hillel Yaffe Hospital in Israel.

On April 17, the 'seed to medicine' company announced receiving approvals for this trial from the two Israel-based hospitals.

"This is a very exciting milestone for the company and the trial, and we look forward to updating our shareholders on results as they come to hand," Co-founder and Managing Director Roby Zomer said.

The trial will be conducted over 14 days per patient and is expected to conclude recruitment in September, with results available the following month.

The results from the trial will provide data points for future trials and will help to facilitate discussions about the potential supply and sale of the ArtemiC product.

Company shares are trading flat at 2.7 cents each at 11:26 am AEST.


Subscribe


MXC by the numbers
More From The Market Herald
Micro X (ASX:MX1) - CEO, Peter Rowland - The Market Herald

" Micro-X (ASX:MX1) ships $500K of x-ray machines over May

X-ray tech specialist Micro-X (MX1) has filled $500,000 worth of orders for its Carestream DRX Revolution Nano product in the month of May
Skin Elements (ASX:SKN) - Executive Chairman, Peter Malone - The Market Herald

" Skin Elements (ASX:SKN) SE Formula 99.99pc effect against coronavirus

Skin Elements’ (SKN) natural plant-based SE Formula has been proven 99.99 per cent effective against Feline coronavirus, a surrogate of COVID-19. Both the...
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep (ASX:IMM) receives A$3.6M from French Govt.

Biotech company, Immutep (IMM) has received $3.6 million (€2,173,454) from the French Government.
Acrux (ASX:ACR) - Managing Director & CEO, Michael Kotsanis - The Market Herald

" Acrux (ASX:ACR) signs sales and distribution agreement with TruPharma

Acrux (ACR) has announced its subsidiary, Acrux DDS, has entered a 10-year exclusive sales, marketing and distribution agreement with TruPharma in the U.S.